| scholarly article | Q13442814 |
| P50 | author | Miguel A Sanz | Q54544774 |
| P2093 | author name string | L Larrea | |
| J de la Rubia | |||
| M L Marty | |||
| D Linares | |||
| N Carpio | |||
| F Arriaga | |||
| P2860 | cites work | Response to plasma exchange and steroids as combined therapy for patients with thrombotic thrombocytopenic purpura | Q33329930 |
| Therapeutic plasma exchange: an update from the Canadian Apheresis Group | Q33330117 | ||
| Management of thrombotic thrombocytopenic purpura | Q33333063 | ||
| Viral inactivation of fresh frozen plasma | Q33992794 | ||
| Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. | Q50517766 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombocytopenia | Q585285 |
| P304 | page(s) | 721-723 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura | |
| P478 | volume | 114 |
| Q50473987 | A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. |
| Q37776318 | A comparison of methods of pathogen inactivation of FFP |
| Q30441694 | A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura |
| Q43744630 | Coagulation factor content of plasma produced from whole blood stored for 24 hours at ambient temperature: results from an international multicenter BEST Collaborative study. |
| Q33368173 | Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light |
| Q46978173 | Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen |
| Q33360121 | Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura |
| Q34310415 | Component pathogen inactivation: a critical review |
| Q33376161 | Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura |
| Q37201179 | Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma? |
| Q56675460 | Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant |
| Q33401403 | Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies |
| Q53674609 | Guidelines on transfusion for fetuses, neonates and older children. |
| Q26741073 | Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use |
| Q33395696 | Investigational drugs in thrombotic thrombocytopenic purpura. |
| Q50500906 | Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. |
| Q33396311 | Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction |
| Q33360800 | Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. |
| Q96813845 | Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data |
| Q44301497 | Methylene-blue-photoinactivated plasma and its contribution to blood safety |
| Q104063169 | Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice |
| Q78370916 | Practical guidelines for the clinical use of plasma |
| Q37026225 | Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies |
| Q46423794 | Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments |
| Q37209117 | Recommendations for the transfusion of plasma and platelets |
| Q37062415 | Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma |
| Q50483769 | The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. |
| Q33344705 | Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes |
| Q33370956 | Treatment of thrombotic thrombocytopenic purpura. |
| Q33418125 | Trends in the diagnosis and management of TTP: European perspective |
| Q33424405 | Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study. |
| Q38109665 | Update on the use of pathogen-reduced human plasma and platelet concentrates |
| Q37166900 | Updates on pathogen inactivation of plasma using Theraflex methylene blue system |
| Q37789774 | Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period |
| Q33348253 | Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura |
| Q35856158 | What is happening? Are the current acceptance criteria for therapeutic plasma adequate? |
| Q90281463 | When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP |
Search more.